Adaptive Biotechnologies Corporation Stock
Equities
ADPT
US00650F1093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.62 USD | -4.73% | +1.55% | -46.53% |
Financials (USD)
Sales 2024 * | 176M | Sales 2025 * | 221M | Capitalization | 405M |
---|---|---|---|---|---|
Net income 2024 * | -193M | Net income 2025 * | -145M | EV / Sales 2024 * | 1.76 x |
Net cash position 2024 * | 96.2M | Net cash position 2025 * | 242M | EV / Sales 2025 * | 0.74 x |
P/E ratio 2024 * |
-2.1
x | P/E ratio 2025 * |
-2.57
x | Employees | 709 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.6% |
Latest transcript on Adaptive Biotechnologies Corporation
1 day | -4.73% | ||
1 week | +1.55% | ||
1 month | -18.38% | ||
3 months | -28.61% | ||
6 months | -40.99% | ||
Current year | -46.53% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Robins
FOU | Founder | 51 | 09-09-07 |
Chad Robins
CEO | Chief Executive Officer | 49 | 09-09-07 |
Kyle Piskel
DFI | Director of Finance/CFO | 40 | 21-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 13-01-31 |
Peter Neupert
BRD | Director/Board Member | 68 | 13-12-31 |
Michael Pellini
BRD | Director/Board Member | 58 | 18-02-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 1 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 2.62 | -4.73% | 1,508,537 |
24-04-29 | 2.75 | +5.77% | 1,638,992 |
24-04-26 | 2.6 | -0.38% | 1,074,607 |
24-04-25 | 2.61 | +0.38% | 1,839,185 |
24-04-24 | 2.6 | +0.78% | 2,020,667 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.53% | 405M | |
-19.78% | 10.81B | |
+44.90% | 3.36B | |
-33.46% | 2.22B | |
-14.31% | 2.16B | |
-28.86% | 1.55B | |
+25.34% | 1.04B | |
-3.28% | 746M | |
-35.33% | 425M | |
+17.30% | 378M |
- Stock Market
- Equities
- ADPT Stock